Thyroid Tablet
FDA Recall NDC 69680-166
Latest: Class I · Status: Ongoing · Initiated Aug 21, 2026 · 1 enforcement report
Active & Historical Enforcement Reports
The FDA has identified 1 recorded enforcement report(s) associated with Thyroid (NDC 69680-166). A significant event, classified as Class I, was initiated on Aug 21, 2026 by Vitruvias Therapeutics. The reported reason for this action was: "Superpotent Drug"
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.
Reported Recall Events
Class I Ongoing
Superpotent Drug
Aug 21, 2026
Sep 23, 2026
1955 bottles
Recall Profile & Regulatory Data
Event ID
99709
Classification
Class I
Enforcement Status
Ongoing
Recalling Firm
VITRUVIAS THERAPEUTICS INC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide.
Product Description
Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.
Batch or Lot Expiration Information
Lot# 504950, Exp Date: 09/30/2026.
Affected Packages Involved in this Recall
69680-165-00Thyroid
69680-166-00Thyroid
69680-167-00Thyroid
69680-168-00Thyroid
69680-169-00Thyroid
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.
